We found that Prmt3 KO dramatically improved the response of tumor-bearing mice to anti-PD1 therapy using the Hepa1-6 model that displays a modest response to anti-PD1 therapy (Fig. 8A, B and Supplementary Fig. 12A, B). The gene discussed is PRMT3; the disease is neoplasm.